Oct 14, 2024
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
Jul 08, 2024
PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
May 22, 2024
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
Apr 22, 2024
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
Jan 23, 2024
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
Jan 11, 2021
PharmAbcine announces a research collaboration with LegoChem Biosciences
Jan 04, 2021
PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"
Dec 09, 2020
PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
Dec 07, 2020
PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020
Nov 16, 2020
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
Sep 21, 2020
PharmAbcine expands partnership with Samsung Biologics for PMC-403
Sep 02, 2020
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
Sep 02, 2020
PharmAbcine is presenting at the KSMO 2020
Aug 03, 2020
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
Jun 26, 2020
PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex
Jun 10, 2020
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
Apr 05, 2020
Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment